Evaluation of Hydroxy Choloroquine on Generalized Vitiligo Vulgaris

Evaluation of oral Hydroxy Choloroquine on treatment of Generalized Vitiligo Vulgaris

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201212049690N1

Enrollment

Registered

2020-12-28

Start date

2019-05-22

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Vitiligo vulgaris. Vitiligo

Interventions

Intervention group: HCQ was orally administered 400 mg daily (~6.5 mg/Kg of body weight) by 15 patients with generalized vitiligo for three months. Patients were evaluated monthly and skin re-pigmenta

Eligibility

Sex/Gender

All

Age

7 Years to No maximum

Inclusion criteria

Inclusion criteria: Involvement of at least 10% of body surface At least one month has passed since the last treatment for the patient Not receiving any other treatment Not taking other drugs at the same time with immunomodulatory and immunosuppressive effects Over 7 years old Weight over 35 kg Do not take drugs that interfere with hydroxychloroquine, such as Image result for artemether and Dapsone and Lumfanterin

Exclusion criteria

Exclusion criteria: Glucose-6-phosphate dehydrogenase deficiency Retinopathy Acute gastrointestinal disorders Myasthenia gravis Psoriasis Renal failure Sensitivity to antimalarial compounds Hepatic failure

Design outcomes

Primary

Measure	Time frame
Score in Vasi Score. Timepoint: Before starting treatment, one-two-three month after start using drug. Method of measurement: Vasi Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoudabeh Sazgarnia

Islamic Azad University

soodabe.sn@gmail.com+98 21 3761 5556

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026